DGX

$195.26+1.10 (+0.57%)

Market ClosedAs of Mar 20, 8:00 PM UTC

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally.

Recent News

Barchart
Mar 19, 2026

How Is Quest Diagnostics’ Stock Performance Compared to Other Healthcare Stocks?

Quest Diagnostics has outpaced its healthcare peers over the past year, and analysts are maintaining a moderately positive outlook on its future performance.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 18, 2026

Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Option Care Health and Addus HomeCare

DGX, DVA, OPCH and ADUS gain attention as telehealth, AI adoption and aging population drive growth in home healthcare services.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 18, 2026

1 Healthcare Stock with Exciting Potential and 2 We Avoid

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 3.6% gain over the past six months, beating the S&P 500 by 2.3 percentage points.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 18, 2026

Elanco Animal Health (ELAN) Surges 7.6%: Is This an Indication of Further Gains?

Elanco Animal Health (ELAN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 17, 2026

A Look At Quest Diagnostics (DGX) Valuation After Recent Share Price Softness

Event overview and recent stock performance Quest Diagnostics (DGX) has been drawing attention after recent share price moves, with the stock down 0.4% over the past day and 1.3% over the past week, while remaining positive over the past 3 months and over the past year. See our latest analysis for Quest Diagnostics. Short term share price weakness contrasts with firmer momentum over longer periods, with the recent 3 month share price return of 11.35% and 1 year total shareholder return of...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.